An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses

[1]  H. Yoshida,et al.  Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. , 2008, Antiviral research.

[2]  Michele A. Kutzler,et al.  DNA vaccines: ready for prime time? , 2008, Nature Reviews Genetics.

[3]  K. Yuen,et al.  Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection1 , 2008, The Journal of Immunology.

[4]  L. Otvos,et al.  Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse , 2007, Virology Journal.

[5]  Chih-Jen Wei,et al.  Immunization by Avian H5 Influenza Hemagglutinin Mutants with Altered Receptor Binding Specificity , 2007, Science.

[6]  Yong Poovorawan,et al.  New Strain of Influenza A Virus (H5N1), Thailand , 2007, Emerging infectious diseases.

[7]  T. Tumpey,et al.  Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1 , 2007, Emerging infectious diseases.

[8]  Gavin J. D. Smith,et al.  Emergence and predominance of an H5N1 influenza variant in China , 2006, Proceedings of the National Academy of Sciences.

[9]  Yan Guo,et al.  Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model , 2006, Vaccine.

[10]  S. Tsiodras.  Suspect Human Cases During the Period of Confirmed Avian Influenza A (H5N1) in Migratory Birds in Greece , 2006 .

[11]  Gavin J. D. Smith,et al.  H5N1 Influenza Viruses in Lao People’s Democratic Republic , 2006, Emerging infectious diseases.

[12]  S. Howie,et al.  "Dirty little secrets"--endotoxin contamination of recombinant proteins. , 2006, Immunology letters.

[13]  E. Holmes,et al.  Host Species Barriers to Influenza Virus Infections , 2006, Science.

[14]  H. Quigley,et al.  Dirty little secrets , 2006, Clinical & experimental ophthalmology.

[15]  Y. Guan,et al.  Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Y. Guan,et al.  H5N1 Outbreaks and Enzootic Influenza , 2006, Emerging infectious diseases.

[17]  Yoshihiro Kawaoka,et al.  Influenza: lessons from past pandemics, warnings from current incidents , 2005, Nature Reviews Microbiology.

[18]  Ying-hua Chen,et al.  Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. , 2005, Microbes and infection.

[19]  J. Shiver,et al.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. , 2004, Vaccine.

[20]  Y. Guan,et al.  Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia , 2004, Nature.

[21]  W. Fiers,et al.  A "universal" human influenza A vaccine. , 2004, Virus research.

[22]  Ying-hua Chen,et al.  Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. , 2004, Immunology letters.

[23]  A. Jegerlehner,et al.  Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity , 2004, The Journal of Immunology.

[24]  L. Otvos,et al.  Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. , 2003, Vaccine.

[25]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[26]  J. Tam,et al.  Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. , 1991, Science.

[27]  R. Lamb,et al.  Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. , 1991, Virology.

[28]  A. Hay,et al.  Structural characteristics of the M2 protein of influenza a viruses: Evidence that it forms a tetrameric channe , 1991, Virology.

[29]  J. Tam,et al.  Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Lamb,et al.  Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions , 1988, Journal of virology.

[31]  J. Tam,et al.  A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain. , 1988, The Journal of biological chemistry.

[32]  V. Caviness.  Long-Term High-Titer Neutralizing Activity Induced by Octameric Synthetic HIV-1 Antigen , 2006 .

[33]  W. C. Gamble,et al.  Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. , 1995, Vaccine.

[34]  J. Tam,et al.  A Novel Method for Producing Anti-peptide Antibodies , 1988 .